IP Library Granted Patent US 10,570,200
Granted Patent B2
US 10,570,200 · App. 14/170,118 · Granted Feb 25, 2020

Antibody-mediated immunocontraception

Inventors: Bruce A. Hay (Pasadena, CA); Juan Li (Pasadena, CA)
Assignee: California Institute of Technology
C07K16/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,570,200
App. No.
14/170,118
Granted
Feb 25, 2020
Kind
B2
Abstract

The present disclosure generally relates to methods and compositions for contraception. In some embodiments, vector based approaches for contraception are provided.

Claims (25)

1. A recombinant genetic construct comprising an antibody gene that encodes an antibody or a fragment thereof that binds to a protein, a peptide, or a small molecule specific to reproductive function, wherein the recombinant genetic construct is configured to be delivered and expressed in an animal subject, wherein the antibody comprises an amino acid sequence that is at least 90% identical to that in SEQ ID NOs: 10, 12, 13, or 14.

2. The recombinant genetic construct of claim 1 , wherein the antibody inhibits a protein specific to reproductive function.

3. The recombinant genetic construct of claim 1 , wherein the protein specific to reproductive function is one that, when bound by the antibody, causes sterility.

4. The recombinant genetic construct of claim 1 , wherein the protein is a reproductive hormone, a protein component of the egg zona pellucida, or a protein component of the sperm plasma membrane.

5. The recombinant genetic construct of claim 1 , wherein the amino acid sequence is at least 95% identical to that in SEQ ID NOs: 10, 12, 13, or 14.

6. The recombinant genetic construct of claim 1 , wherein the amino acid sequence is at least 99% identical to that in SEQ ID NOs: 10, 12, 13, or 14.

7. The recombinant genetic construct of claim 1 , wherein the antibody comprises 6 CDRs, wherein the 6 CDRs are 6 CDRs are encoded by SEQ ID NOs:10 and 12, or 13 and 14.

8. The recombinant genetic construct of claim 1 , wherein the antibody comprises an amino acid sequence SEQ ID NOs: 10, 12, 13, or 14.

9. The recombinant genetic construct of claim 1 , wherein the antibody comprises SEQ ID NOs:

a) 10 and 12, or

b) 13 and 14.

10. The recombinant genetic construct of claim 1 , wherein the antibody comprises an amino acid sequence that is at least 90% identical to that in SEQ ID NO: 12.

11. The recombinant genetic construct of claim 1 , wherein the antibody comprises an amino acid sequence that is at least 90% identical to that in SEQ ID NO: 13.

12. The recombinant genetic construct of claim 1 , wherein the antibody or fragment thereof comprises an amino acid modification that enhances or suppresses an effector function of the encoded antibody or fragment.

13. The recombinant genetic construct of claim 1 , comprising an antibody expression cassette comprising a tissue specific promoter, a regulatory element, and one or more microRNA target sites.

14. The recombinant genetic construct of claim 13 , wherein the regulatory element is a 5′ untranslated region (5′ UTR) or a 3′ untranslated region (3′ UTR).

15. The recombinant genetic construct of claim 1 , incorporated into a transfection vehicle selected from the group consisting of an adeno-associated virus (AAV), a lentivirus, a DNA-containing nanoparticle, a liposome-DNA mixture, and a peptide-DNA mixture.

16. A contraceptive composition comprising the recombinant genetic construct of claim 1 .

17. The contraceptive composition of claim 16 , configured to be delivered to an animal through intramuscular injection, subcutaneous injection, intravenous injection, intraperitoneal injection, oral delivery, electroporation through the skin, sonication, or nasal inhalation.

18. A pharmaceutical composition comprising:

the recombinant genetic construct of claim 1 ; and

a pharmaceutically acceptable carrier, wherein the recombinant genetic construct is present in at least 1 ug/ml, and wherein the pharmaceutically acceptable carrier can be combined with a nucleic acid.

19. The recombinant genetic construct of claim 1 , wherein the antibody comprises 3 CDRs, wherein the 3 CDRs are 3 CDRs are encoded by SEQ ID NO: 28.

20. The recombinant genetic construct of claim 1 , wherein the antibody comprises 3 CDRs, wherein the 3 CDRs are 3 CDRs are encoded by SEQ ID NO: 35.

21. The recombinant genetic construct of claim 1 , wherein the antibody comprises an amino acid sequence that is at least 90% identical to that in SEQ ID NO: 14.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 24, 2016
From: HAY, BRUCE A.; LI, JUAN
To: CALIFORNIA INSTITUTE OF TECHNOLOGY
Reel/Frame 039530/0689 →
CONFIRMATORY LICENSE Recorded Mar 5, 2014
From: CALIFORNIA INSTITUTE OF TECHNOLOGY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 032387/0484 →
Continuity (2)
Provisional Application 61759788 · Feb 1, 2013
Related Publication 20140223591A1 · Aug 7, 2014
Cited By (2)
US 12,213,468 US 12,577,583